Shattuck Labs (NASDAQ:STTK) Issues Earnings Results

Shattuck Labs (NASDAQ:STTK) released its quarterly earnings results on Thursday. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.01, Zacks reports. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%.

Shattuck Labs Stock Down 7.5 %

Shares of NASDAQ:STTK opened at $1.06 on Friday. Shattuck Labs has a fifty-two week low of $0.94 and a fifty-two week high of $11.76. The firm’s 50 day moving average price is $1.24 and its 200 day moving average price is $1.49. The stock has a market cap of $50.37 million, a price-to-earnings ratio of -0.69 and a beta of 1.66.

Wall Street Analyst Weigh In

Several research firms recently issued reports on STTK. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a research report on Thursday. Leerink Partners began coverage on shares of Shattuck Labs in a research note on Monday, March 17th. They issued an “outperform” rating and a $4.00 price objective for the company. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a research note on Thursday. Four analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.